Los Angeles Capital Management LLC Has $2.77 Million Holdings in Kenvue Inc. $KVUE

Los Angeles Capital Management LLC grew its position in Kenvue Inc. (NYSE:KVUE) by 28.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 160,814 shares of the company’s stock after purchasing an additional 35,263 shares during the period. Los Angeles Capital Management LLC’s holdings in Kenvue were worth $2,774,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Physician Wealth Advisors Inc. increased its position in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. Elyxium Wealth LLC acquired a new position in Kenvue in the 4th quarter worth about $26,000. SBI Securities Co. Ltd. increased its holdings in shares of Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after acquiring an additional 1,027 shares during the last quarter. Leonteq Securities AG acquired a new position in shares of Kenvue during the 4th quarter valued at about $45,000. Finally, Hantz Financial Services Inc. increased its holdings in shares of Kenvue by 157.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,850 shares of the company’s stock valued at $46,000 after acquiring an additional 1,742 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

KVUE opened at $17.91 on Wednesday. The firm has a market capitalization of $34.38 billion, a P/E ratio of 21.06, a price-to-earnings-growth ratio of 1.33 and a beta of 0.54. The stock’s 50 day moving average price is $17.38 and its two-hundred day moving average price is $17.51. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $22.87.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company’s revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.24 EPS. On average, equities analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Activity at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on KVUE. Citigroup lowered their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Canaccord Genuity Group increased their price target on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Finally, UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.